Q1 Earnings Forecast for electroCore Issued By HC Wainwright

electroCore, Inc. (NASDAQ:ECOR - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of electroCore in a research report issued on Thursday, May 7th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.37) per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for electroCore's current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for electroCore's Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.06) EPS and Q4 2027 earnings at $0.08 EPS.electroCore (NASDAQ:ECOR - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.59) EPS for the quarter, meeting the consensus estimate of ($0.59). The company had revenue of $9.58 million during the quarter, compared to analysts' expectations of $9.01 million. electroCore had a negative net margin of 44.08% and a negative return on equity of 1,956.38%. A number of other analysts have also recently commented on the stock. upgraded shares of electroCore to a "strong-buy" rating in a research report on Tuesday, February 3rd. Zacks Research upgraded shares of electroCore from a "strong sell" rating to a "hold" rating in a research report on Friday, March 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of electroCore in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $18.00.Check Out Our Latest Analysis on ECORelectroCore Stock PerformanceShares of electroCore stock opened at $6.41 on Monday. The firm has a fifty day moving average of $6.58 and a two-hundred day moving average of $5.88. The stock has a market capitalization of $53.20 million, a price-to-earnings ratio of -3.62 and a beta of 0.68. electroCore has a 52 week low of $4.16 and a 52 week high of $8.64. Institutional Investors Weigh In On electroCoreSeveral hedge funds have recently bought and sold shares of ECOR. NewEdge Advisors LLC lifted its stake in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company's stock valued at $1,083,000 after purchasing an additional 145,047 shares during the last quarter. Tejara Capital Ltd acquired a new stake in electroCore in the 4th quarter valued at about $450,000. DRW Securities LLC acquired a new stake in electroCore in the 4th quarter valued at about $264,000. WealthShield Partners LLC acquired a new stake in electroCore in the 1st quarter valued at about $157,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in electroCore in the 1st quarter valued at about $153,000. 26.74% of the stock is currently owned by institutional investors and hedge funds. Insider Activity at electroCoreIn other news, Director Daniel S. Goldberger sold 16,072 shares of the stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $6.02, for a total transaction of $96,753.44. Following the completion of the transaction, the director directly owned 291,471 shares in the company, valued at $1,754,655.42. This represents a 5.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.80% of the stock is currently owned by corporate insiders. electroCore Company Profile (Get Free Report)electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device. The company's lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.See AlsoFive stocks we like better than electroCoreBeyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumQuantum Earnings Season Is Ramping Up—What to Watch From 2 Major PlayersFlutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in electroCore Right Now?Before you consider electroCore, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.While electroCore currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here